Short answer
QuidelOrtho Corp (QDEL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 27, 2026. Quarterly revenue was $619M (down 11.6% year over year) with net income of −$54M.
Q3 2026 key financials · XBRL
- Revenue
- $619M
- −11.6% YoY · −1.9% QoQ
- Net income
- −$54M
- +92.7% YoY · +42.1% QoQ
- Operating margin
- -1.2%
- EPS (diluted)
- −$0.78
- +92.8% YoY · +42.6% QoQ
Source: XBRL data from the QuidelOrtho Corp (QDEL) Q3 2026 10-Q on SEC EDGAR. USD.
QuidelOrtho Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $618.9M, down 12% YoY from $699.9M
- Cost of sales margin 53.2% vs 52.1% YoY, implying gross margin 46.8% vs 47.9%
- Best line Immunohematology $142.0M, flat YoY; worst Donor Screening $1.7M, down 88% from $14.7M
- Cash $166.4M, down $3.4M; operating cash flow used $124.0M through nine months
- Outlook: weaker respiratory season may persist; China pricing changes and tariffs remain headwinds, with over $80M annual savings targeted for 2027
Risk Factors
- No material changes to risk factors since the Annual Report
- Significant indebtedness, potentially limiting financial flexibility
- Dependence on product development and commercialization success
- Healthcare regulatory approvals and compliance requirements
- Intense competition in in-vitro diagnostics markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other QuidelOrtho Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.